Logo image of NEUE

NEUEHEALTH INC (NEUE) Stock Fundamental Analysis

NYSE:NEUE - New York Stock Exchange, Inc. - US10920V4041 - Common Stock

7.37  -0.08 (-1.07%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to NEUE. NEUE was compared to 108 industry peers in the Health Care Providers & Services industry. NEUE may be in some trouble as it scores bad on both profitability and health. NEUE does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year NEUE was profitable.
In the past year NEUE has reported a negative cash flow from operations.
In the past 5 years NEUE always reported negative net income.
The reported operating cash flow has been mixed in the past 5 years: NEUE reported negative operating cash flow in multiple years.
NEUE Yearly Net Income VS EBIT VS OCF VS FCFNEUE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 0 -500M -1B -1.5B -2B -2.5B

1.2 Ratios

NEUE's Return On Assets of -110.18% is on the low side compared to the rest of the industry. NEUE is outperformed by 94.39% of its industry peers.
Industry RankSector Rank
ROA -110.18%
ROE N/A
ROIC N/A
ROA(3y)-54.32%
ROA(5y)-38.39%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
NEUE Yearly ROA, ROE, ROICNEUE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 0 100 -100 200 -200 300

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for NEUE so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NEUE Yearly Profit, Operating, Gross MarginsNEUE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 -20 -40 -60 -80 -100

More info and screens

3

2. Health

2.1 Basic Checks

NEUE does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for NEUE has been increased compared to 1 year ago.
The debt/assets ratio for NEUE is higher compared to a year ago.
NEUE Yearly Shares OutstandingNEUE Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2M 4M 6M 8M
NEUE Yearly Total Debt VS Total AssetsNEUE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 1B 2B 3B 4B

2.2 Solvency

NEUE has an Altman-Z score of -5.78. This is a bad value and indicates that NEUE is not financially healthy and even has some risk of bankruptcy.
NEUE has a worse Altman-Z score (-5.78) than 88.78% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -5.78
ROIC/WACCN/A
WACC9.66%
NEUE Yearly LT Debt VS Equity VS FCFNEUE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 0 1B -1B -2B

2.3 Liquidity

NEUE has a Current Ratio of 3.45. This indicates that NEUE is financially healthy and has no problem in meeting its short term obligations.
NEUE's Current ratio of 3.45 is amongst the best of the industry. NEUE outperforms 89.72% of its industry peers.
A Quick Ratio of 3.45 indicates that NEUE has no problem at all paying its short term obligations.
NEUE has a better Quick ratio (3.45) than 89.72% of its industry peers.
Industry RankSector Rank
Current Ratio 3.45
Quick Ratio 3.45
NEUE Yearly Current Assets VS Current LiabilitesNEUE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 200M 400M 600M 800M 1B

More info and screens

3

3. Growth

3.1 Past

NEUE shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 102.44%, which is quite impressive.
Looking at the last year, NEUE shows a very negative growth in Revenue. The Revenue has decreased by -51.87% in the last year.
Measured over the past years, NEUE shows a very strong growth in Revenue. The Revenue has been growing by 54.80% on average per year.
EPS 1Y (TTM)102.44%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%54.04%
Revenue 1Y (TTM)-51.87%
Revenue growth 3Y31.12%
Revenue growth 5Y54.8%
Sales Q2Q%-13.54%

3.2 Future

The Earnings Per Share is expected to decrease by -33.13% on average over the next years. This is quite bad
NEUE is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -5.16% yearly.
EPS Next Y-128.83%
EPS Next 2Y-33.13%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-26.98%
Revenue Next 2Y-10.61%
Revenue Next 3Y-5.16%
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
NEUE Yearly Revenue VS EstimatesNEUE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2B 4B 6B
NEUE Yearly EPS VS EstimatesNEUE Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 -50 -100

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 5.58, the valuation of NEUE can be described as very cheap.
Based on the Price/Earnings ratio, NEUE is valued cheaply inside the industry as 99.07% of the companies are valued more expensively.
When comparing the Price/Earnings ratio of NEUE to the average of the S&P500 Index (28.29), we can say NEUE is valued rather cheaply.
NEUE is expected to report negative earnings next year, which makes the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE 5.58
Fwd PE N/A
NEUE Price Earnings VS Forward Price EarningsNEUE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NEUE Per share dataNEUE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 100 -100 -200

4.3 Compensation for Growth

A cheap valuation may be justified as NEUE's earnings are expected to decrease with -33.13% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-33.13%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for NEUE!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NEUEHEALTH INC

NYSE:NEUE (1/21/2025, 8:16:47 PM)

7.37

-0.08 (-1.07%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)11-07 2024-11-07/bmo
Earnings (Next)N/A N/A
Inst Owners54.57%
Inst Owner ChangeN/A
Ins Owners6.3%
Ins Owner Change22.11%
Market Cap61.10M
Analysts45
Price Target19.89 (169.88%)
Short Float %0.3%
Short Ratio0.53
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-79.05%
Min EPS beat(2)-118.63%
Max EPS beat(2)-39.47%
EPS beat(4)1
Avg EPS beat(4)80.65%
Min EPS beat(4)-118.63%
Max EPS beat(4)572.52%
EPS beat(8)3
Avg EPS beat(8)33.15%
EPS beat(12)3
Avg EPS beat(12)-17.41%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-7.78%
Min Revenue beat(2)-12.25%
Max Revenue beat(2)-3.31%
Revenue beat(4)1
Avg Revenue beat(4)-5.35%
Min Revenue beat(4)-12.25%
Max Revenue beat(4)1.3%
Revenue beat(8)2
Avg Revenue beat(8)-13.77%
Revenue beat(12)2
Avg Revenue beat(12)-44.62%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)10.38%
PT rev (3m)10.38%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-1.18%
Valuation
Industry RankSector Rank
PE 5.58
Fwd PE N/A
P/S 0.06
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)1.32
EY17.91%
EPS(NY)-12.16
Fwd EYN/A
FCF(TTM)-251.03
FCFYN/A
OCF(TTM)-250.87
OCFYN/A
SpS124.65
BVpS-46.61
TBVpS-55.78
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -110.18%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-54.32%
ROA(5y)-38.39%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover1.15
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 8.22%
Cap/Sales 0.13%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.45
Quick Ratio 3.45
Altman-Z -5.78
F-Score2
WACC9.66%
ROIC/WACCN/A
Cap/Depr(3y)50.59%
Cap/Depr(5y)60.56%
Cap/Sales(3y)1.13%
Cap/Sales(5y)0.99%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)102.44%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%54.04%
EPS Next Y-128.83%
EPS Next 2Y-33.13%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-51.87%
Revenue growth 3Y31.12%
Revenue growth 5Y54.8%
Sales Q2Q%-13.54%
Revenue Next Year-26.98%
Revenue Next 2Y-10.61%
Revenue Next 3Y-5.16%
Revenue Next 5YN/A
EBIT growth 1Y59.13%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year103.59%
EBIT Next 3Y27.76%
EBIT Next 5YN/A
FCF growth 1Y-852.1%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-767.21%
OCF growth 3YN/A
OCF growth 5YN/A